NCT05743959 is a clinical trial of No intervention in Biliary Tract Cancer, sponsored by The First Affiliated Hospital with Nanjing Medical University.

Who is sponsoring NCT05743959?

NCT05743959 is sponsored by The First Affiliated Hospital with Nanjing Medical University.

What drugs are being tested in NCT05743959?

Interventions in NCT05743959: No intervention.

What condition does NCT05743959 study?

NCT05743959 studies Biliary Tract Cancer.

Is NCT05743959 still recruiting?

NCT05743959 is currently status unknown. Last updated 22 May 2023.

Last reviewed 2023-05-22 · How we verify

NCT05743959

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial

Status unknown Last updated 22 May 2023

What this trial tests

trial testing No intervention in Biliary Tract Cancer in 100 participants. Status unknown.

Timeline

1 May 2022

Primary endpoint
30 December 2024

30 December 2025

Quick facts

Lead sponsor	The First Affiliated Hospital with Nanjing Medical University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 May 2022
Primary completion	30 December 2024
Estimated completion	30 December 2025
Sites	1 location across China

Drugs / interventions tested

No intervention

Conditions studied

Biliary Tract Cancer — all drugs for Biliary Tract Cancer →

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Who can join

18 and older, any sex, with Biliary Tract Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A substantial proporation of patients with biliary tract malignancies still experience disease recurrence after curative resection. ctDNA-based minimal residual disease (MRD) method has been widely used to monitor postoperative recurrence in solid cancers, but few studies have been reported in biliary tract cancers. The present clinical trial aims to elucidate the correlation between the postoperative ctDNA status and the prognosis of patients with biliary tract cancers, and evaluate whether ctDNA could better predict patients' recurrence and guide clinical practice.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Integration of circulating tumor DNA in biliary tract cancer: the emerging landscape.
Awosika JA, Monge C, Greten TF. · · 2024 · cited 6× · PMID 39881555 · DOI 10.1080/20450923.2024.2403334
Biliary tract cancers: advances in diagnostic and management.
Gutmans J, Mechahougui H. · · 2025 · cited 1× · PMID 40585845 · DOI 10.37349/etat.2025.1002328

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting

Other recruiting trials for Biliary Tract Cancer

Currently open trials in the same condition.

NCT07221253 — A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Bili · Phase 3 · recruiting
NCT06529718 — Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients · Phase 2 · recruiting
NCT07151118 — ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer · recruiting
NCT07142226 — Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC · recruiting
NCT07135544 — A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initial · Phase 2 · recruiting

Other The First Affiliated Hospital with Nanjing Medical University trials

Trials by the same sponsor.

NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07523789 — Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC · not yet recruiting
NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
NCT07482826 — Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis · NA · not yet recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05743959 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital with Nanjing Medical University
Last refreshed: 22 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05743959.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing